MK-2870 in Post Platinum and Post Immunotherapy Endometrial Cancer

Phase 1

Recruiting

• Conditions: Endometrial cancer; MedDRA version: 21.0Level: LLTClassification code: 10014735Term: Endometrial cancer NOS Class: 10029104; Therapeutic area: Diseases [C] - Neoplasms [C04]

• Registration Number: CTIS2023-504816-14-00
• Lead Sponsor: Merck Sharp & Dohme LLC

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2023-10-20
• Last Update Posted: 21 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 690

Inclusion Criteria

Histologically-confirmed diagnosis of endometrial carcinoma or carcinosarcoma., Radiographically evaluable disease, either measurable or nonmeasurable per RECIST 1.1, as assessed by BICR., Received prior platinum-based chemotherapy and anti- programmed cell death 1 protein (PD-1)/anti- programmed cell death ligand 1 (PD-L1) therapy, either separately or in combination.

Exclusion Criteria

Neuroendocrine tumors or endometrial sarcoma, including stromal sarcoma, leiomyosarcoma, adenosarcoma, or other types of pure sarcomas., History of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or corneal disease that prevents/delays corneal healing., Active inflammatory bowel disease requiring immunosuppressive medication or previous history of inflammatory bowel disease., Recurrence of endometrial carcinoma or carcinosarcoma more than 180 days after completing platinum-based therapy administered in the curative-intent or adjuvant setting without any additional platinum-based therapy received in the metastatic or recurrent setting., Received more than 3 prior lines of therapy for endometrial carcinoma or carcinosarcoma.

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified